CFT7455 as a monotherapy for RR MM patients, which is complete; CFT7455 in combination with dexamethasone for RR MM patients, which is still enrolling patients; and CFT7455 as a monotherapy for NHL patients, which is also still enrolling patients.\n\nThe data presented by C4 Therapeutics show promising signs of anti-myeloma and immunomodulatory activity for CFT7455 as a monotherapy. The company has established a 14 days on/14 days off dosing schedule as the optimal regimen, which is consistent with preclinical data supporting CFT7455 as a rationally designed IKZF13 degrader.\n\nIn the monotherapy arm of the trial, 22 heavily pretreated patients with a median of seven prior therapies received CFT7455. The maximum dose administered was 75 µg daily for 14 days on/14 days off, and a maximum tolerated dose was not defined. The majority of patients had received prior CAR-T or T-cell engager therapy.\n\nPharmacokinetic and pharmacodynamic results showed consistent clearance of CFT7455 with a 48-hour half-life. Daily dosing (14 days on/14 days off) resulted in deep IKZF13 degradation, with protein levels recovering after day 14 as plasma concentrations of CFT7455 declined.\n\nCFT7455 was well tolerated, with no dose-limiting toxicities reported. The most common treatment-related adverse events were grade 1 or 2 fatigue, nausea, and diarrhea, and there were no grade 3 or higher treatment-related adverse events. The most common grade 1 or 2 laboratory abnormalities were anemia, lymphopenia, and thrombocytopenia.\n\nC4 Therapeutics will continue to advance the trial, with data from the complete Phase 1 dose escalation portion expected in 2024. The company is also exploring the potential of CFT7455 in combination with dexamethasone for RR MM patients and as a monotherapy for NHL patients.\n\n C4 Therapeutics has presented promising clinical data for CFT7455 in the treatment of multiple myeloma and non-Hodgkin’s lymphomas.”